Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK

Lancet

Volumn 362, Issue 9378, 2003, Pages 128-130

  Brandel, Jean Philippe ^a   Preece, Michael ^b   Brown, Paul ^c   Croes, Esther ^d   Laplanche, Jean Louis ^e   Agid, Yves ^a   Will, Robert ^f   Alpérovitch, Annick ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e HÔPITAL LARIBOISIÈRE   (France)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE;

ARTICLE; CODON; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; FRANCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; PRION; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

EID: 0038304770     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13867-6     Document Type: Article

References (5)

1. Brown P., Preece M., Brandel J.P., et al. Iatrogenic Creutzfeldt-Jacob disease at the millenium. Neurology. 55:2000;1075-1081.
2. Laplanche J.L., Delasnerie-Laupretre, Brandel J.P., et al. Molecular genetics of prion diseases in France. Neurology. 44:1994;2347-2351.
3. Palmer M.S., Dryden A.J., Hughes J.T., Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 352:1991;340-342.
4. Swerdlow A.J., Higgins C.D., Adlard P., Preece M.A. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet. 360:2002;273-277.
5. Goldmann W, Hunter N, Smith G, Foster J, Hope J. PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. J Gen Virol 1994; 989-95.